Published in ACS Med Chem Lett on October 02, 2014
First Safety Study in Humans of a Single Dose of CPG 52364 | NCT00547014
Small-molecule inhibition of TLR8 through stabilization of its resting state. Nat Chem Biol (2017) 0.75
Pathogen recognition and innate immunity. Cell (2006) 44.14
A Toll-like receptor recognizes bacterial DNA. Nature (2000) 26.34
Toll-like receptors in innate immunity. Int Immunol (2005) 12.24
TLR signaling. Semin Immunol (2007) 8.16
The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov (2007) 6.27
Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity (2006) 6.00
Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. Proc Natl Acad Sci U S A (2004) 4.88
Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. Eur J Immunol (2004) 2.80
Pathogen recognition by innate receptors. J Infect Chemother (2008) 2.16
Toll-like receptor 9 inhibition reduces mortality in polymicrobial sepsis. J Exp Med (2008) 1.89
Unc93B1 restricts systemic lethal inflammation by orchestrating Toll-like receptor 7 and 9 trafficking. Immunity (2011) 1.59
Critical role of TLR7 in the acceleration of systemic lupus erythematosus in TLR9-deficient mice. J Autoimmun (2009) 1.51
Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry. J Med Chem (2011) 1.45
Therapeutical targeting of nucleic acid-sensing Toll-like receptors prevents experimental cerebral malaria. Proc Natl Acad Sci U S A (2011) 1.44
The future of toll-like receptor therapeutics. Curr Opin Mol Ther (2008) 1.05
Rapid assessment of a novel series of selective CB(2) agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis. Bioorg Med Chem Lett (2009) 1.04
Critical role of TLR9 in acute graft-versus-host disease. J Immunol (2008) 1.03
Oligodeoxyribonucleotide-based antagonists for Toll-like receptors 7 and 9. J Med Chem (2009) 0.97
Role of toll-like receptors in multiple sclerosis. Am J Clin Exp Immunol (2013) 0.94
Nucleosome-induced neutrophil activation occurs independently of TLR9 and endosomal acidification: implications for systemic lupus erythematosus. Eur J Immunol (2011) 0.91
A Toll-like receptor 7, 8, and 9 antagonist inhibits Th1 and Th17 responses and inflammasome activation in a model of IL-23-induced psoriasis. J Invest Dermatol (2013) 0.91
Design and synthesis of novel N-hydroxy-dihydronaphthyridinones as potent and orally bioavailable HIV-1 integrase inhibitors. J Med Chem (2011) 0.84
Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design. ACS Med Chem Lett (2012) 0.84
A novel small-molecule enantiomeric analogue of traditional (-)-morphinans has specific TLR9 antagonist properties and reduces sterile inflammation-induced organ damage. J Immunol (2013) 0.83